{{Drugbox
| Watchedfields = changed
| verifiedrevid = 477169407
| IUPAC_name = 3-(10,11-Dihydro-5''H''-dibenzo[''a'',''d'']cycloheptene-5-ylidene)-''N'',''N''-dimethylpropan-1-amine
| image = Amitriptyline2DACS.svg
| width = 200
| image2 = Amitriptyline-from-picrate-xtal-3D-balls.png
| width2 = 250
<!--Clinical data-->
| tradename = Amitrip, Elevil, Endep, Levate
| Drugs.com = {{drugs.com|monograph|amitriptyline-hydrochloride}}
| MedlinePlus = a682388
| licence_US = Amitriptyline
| pregnancy_AU = C
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 口服，肌注
<!--Pharmacokinetic data-->
| bioavailability = 30–60%因经过首过代谢
| protein_bound = 96%<ref name = DM>{{cite web|title=AMITRIPTYLINE HYDROCHLORIDE tablet, film coated [Dispensing Solutions, Inc.]|work=DailyMed|publisher=Dispensing Solutions, Inc.|date=September 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f95829b-4040-49a8-bac4-a845c227c81a|accessdate=1 December 2013|archive-date=2013-12-03|archive-url=https://web.archive.org/web/20131203035328/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f95829b-4040-49a8-bac4-a845c227c81a|dead-url=no}}</ref><ref name = MSR>{{cite web|title=Levate (amitriptyline), dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=1 December 2013|url=http://reference.medscape.com/drug/levate-amitriptyline-342936#showall|archive-date=2013-12-03|archive-url=https://web.archive.org/web/20131203023123/http://reference.medscape.com/drug/levate-amitriptyline-342936#showall|dead-url=no}}</ref><ref name = TGA>{{cite web|title=Endep Amitriptyline hydrochloride|date=10 December 2012|accessdate=1 December 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04558-3|format=PDF|work=TGA eBusiness Services|publisher=Alphapharm Pty Limited|archive-date=2017-08-13|archive-url=https://web.archive.org/web/20170813145944/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04558-3|dead-url=no}}</ref><ref name = EMC>{{cite web|title=Amitriptyline Tablets BP 50mg - Summary of Product Characteristics (SPC)|work=electronic Medicines Compendium|publisher=Actavis UK Ltd|date=24 March 2013|accessdate=1 December 2013|url=http://www.medicines.org.uk/emc/medicine/23738/SPC/Amitriptyline+Tablets+BP+50mg/|archive-date=2013-12-03|archive-url=https://web.archive.org/web/20131203015148/http://www.medicines.org.uk/emc/medicine/23738/SPC/Amitriptyline+Tablets+BP+50mg/|dead-url=no}}</ref>
| metabolism = [[肝脏|肝脏]] ([[CYP2D6|CYP2D6]])<ref name = DM/><ref name = MSR/><ref name = TGA/><ref name = EMC/>
| elimination_half-life = 22.4 小时(26 hr for active metabolite, nortriptyline)<ref name = DM/><ref name = MSR/><ref name = TGA/><ref name = EMC/>
| excretion = [[肾脏|肾脏]]<ref name = DM/><ref name = MSR/><ref name = TGA/><ref name = EMC/>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50-48-6
| CAS_number2 = 549-18-8
| CAS_number2_comment = [[hydrochloride|hydrochloride]]
| ATC_prefix = N06
| ATC_suffix = AA09
| PubChem = 2160
| IUPHAR_ligand = 200
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00321
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2075
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1806D8D52K
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07448
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2666
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 629
<!--Chemical data-->
| C=20 | H=23
| N=1
| molecular_weight = 277.403 g/mol
| smiles = c3cc2c(/C(c1c(cccc1)CC2)=C\CCN(C)C)cc3
| InChI = 1/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
| InChIKey = KRMDCWKBEZIMAB-UHFFFAOYAI
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KRMDCWKBEZIMAB-UHFFFAOYSA-N
}}
{{medical}}
<!-- 醫療用途 -->
'''阿米替林'''（{{lang|en|Amitriptyline}}）<ref>{{Cite web |url=http://www.oxforddictionaries.com/us/definition/english/amitriptyline?q=amitriptyline |title=Oxford Dictionary: Definition of amitriptyline (British & World English) |accessdate=2015-09-26 |archive-date=2014-07-14 |archive-url=https://web.archive.org/web/20140714140116/http://www.oxforddictionaries.com/us/definition/english/amitriptyline?q=amitriptyline |dead-url=no }}</ref>，商品名稱'''Elavil'''，是使用最广泛的一种[[止痛药|止痛药]]。<ref>A.S. Yazdi, N. Razavi, S.R. Yazdinejad. Separation and determination of amitriptyline and nortriptyline by dispersive liquid–liquid microextraction combined with gas chromatography flame ionization detection. Talanta, 75 (2008), pp. 1293–1299</ref> 
阿米替林可以治疗许多[[精神障碍|精神障碍]]<ref name=AHFS2014/>，包括[[重度抑郁症|重度抑郁症]]和[[焦虑症|焦虑症]]，有时候也用来治疗[[精神病|精神病]]、[[注意力缺陷多动障碍|注意力缺陷多动障碍]]（ADHD，多动症）和[[双相情感障碍|双相情感障碍]]<ref name=AHFS2014/><ref>{{cite journal|last1=Leucht|first1=C|last2=Huhn|first2=M|last3=Leucht|first3=S|title=Amitriptyline versus placebo for major depressive disorder.|journal=The Cochrane Database of Systematic Reviews|date=December 2012|volume=12|pages=CD009138|doi=10.1002/14651858.CD009138.pub2|pmid=23235671}}</ref>。阿米替林也可以預防[[偏头痛|偏头痛]]、治療包括[[纖維肌痛症|纖維肌痛症]]及{{le|疱疹後神經痛|postherpetic neuralgia}}在内的[[神經性疼痛|神經性疼痛]]，偶爾也會被用於治療[[失眠|失眠]]<ref name=AHFS2014>{{cite web|title=Amitriptyline Hydrochloride|url=http://www.drugs.com/monograph/amitriptyline-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|accessdate=Sep 25, 2014|archive-date=2014-09-24|archive-url=https://web.archive.org/web/20140924185142/http://www.drugs.com/monograph/amitriptyline-hydrochloride.html|dead-url=no}}</ref><ref name = Coch2015>{{cite journal|last1=Moore|first1=RA|last2=Derry|first2=S|last3=Aldington|first3=D|last4=Cole|first4=P|last5=Wiffen|first5=PJ|title=Amitriptyline for neuropathic pain in adults.|journal=The Cochrane database of systematic reviews|date=6 July 2015|volume=7|pages=CD008242|pmid=26146793}}</ref>。該藥屬於口服藥物<ref name=AHFS2014/>。

<!--副作用及機制 -->
常見的副作用包含口乾、視覺障礙、[[姿位性低血壓|姿位性低血壓]]、嗜睡，以及[[便秘|便秘]]等等<!-- <ref name=AHFS2014/> -->。嚴重的副作用可能會造成[[癲癇發作|癲癇發作]]、[[尿滯留|尿滯留]]、[[青光眼|青光眼]]，或是其他心臟問題<!-- <ref name=AHFS2014/> -->，25歲以下的用藥者甚至會有增加[[自殺|自殺]]念頭的風險<!-- <ref name=AHFS2014/> -->。該藥切忌與[[单胺氧化酶抑制剂|单胺氧化酶抑制剂]]或{{le|希塞菩|cisapride}}等藥物合用<ref name=AHFS2014/>。妊娠時服用阿米替林可能具有風險<ref>{{cite web|title=Prescribing medicines in pregnancy database|url=http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw|work=Australian Government|accessdate=22 April 2014|date=3 March 2014|archive-date=2014-04-08|archive-url=https://web.archive.org/web/20140408040902/http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw|dead-url=no}}</ref><ref name=AHFS2014/>，[[母乳餵養|哺乳]]期間用藥目前認為是安全的<ref>{{cite web|title=Amitriptyline Levels and Effects while Breastfeeding|url=http://www.drugs.com/breastfeeding/amitriptyline.html|website=drugs.com|accessdate=25 September 2014|date=Sep 8, 2014|archive-date=2014-09-24|archive-url=https://web.archive.org/web/20140924182122/http://www.drugs.com/breastfeeding/amitriptyline.html|dead-url=no}}</ref>。該藥為使用最廣泛的一種[[三環類抗抑鬱藥|三環類抗抑鬱藥]]（TCA）<!-- <ref name=AHFS2014/>-->，然其詳細機轉仍不清楚<ref name=AHFS2014/>。

<!-- 歷史、社會及文化 -->
在1960年首次發現阿米替林<ref>{{cite book|last1=Sneader|first1=Walter|title=Drug Discovery a History.|date=2005|publisher=John Wiley & Sons|location=Chichester|isbn=9780470015520|page=414|url=https://books.google.ca/books?id=jglFsz5EJR8C&pg=PA414}}</ref>，並於1961年被[[美國食品藥品監督管理局|美國食品藥品監督管理局]]核准<ref>{{cite journal | author = Fangmann P, Assion HJ, Juckel G, González CA, López-Muñoz F | title = Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics | url = https://archive.org/details/sim_journal-of-clinical-psychopharmacology_2008-02_28_1/page/1 | journal = Journal of Clinical Psychopharmacology | volume = 28 | issue = 1 | pages = 1–4 | date = February 2008 | pmid = 18204333 | doi = 10.1097/jcp.0b013e3181627b60}}</ref>。該藥列名[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]當中，為基礎醫療體系的必備用藥之一<ref>{{cite web|title=WHO Model List of Essential Medicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013|archive-date=2014-04-23|archive-url=https://web.archive.org/web/20140423005004/http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|dead-url=no}}</ref>。該藥屬於[[通用名藥物|通用名藥物]]<ref name=AHFS2014/>，2014年每劑的批發價價格區間位於0.01至0.04美金之間<ref>{{cite web|title=Amitriptyline|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=AMT25T&s_year=2014&year=2014&str=25%20mg&desc=Amitriptyline&pack=new&frm=TAB-CAP&rte=PO&class_code2=24%2E2%2E1%2E&supplement=&class_name=%2802%2E3%2E%29Medicines%20for%20other%20common%20symptoms%20in%20palliative%20care%3Cbr%3E%2824%2E2%2E1%2E%29Medicines%20used%20in%20depressive%20disorders%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=2 December 2015|deadurl=yes|archiveurl=https://web.archive.org/web/20170330174215/http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=AMT25T&s_year=2014&year=2014&str=25%20mg&desc=Amitriptyline&pack=new&frm=TAB-CAP&rte=PO&class_code2=24%2E2%2E1%2E&supplement=&class_name=%2802%2E3%2E%29Medicines%20for%20other%20common%20symptoms%20in%20palliative%20care%3Cbr%3E%2824%2E2%2E1%2E%29Medicines%20used%20in%20depressive%20disorders%3Cbr%3E|archivedate=2017年3月30日}}</ref>，美國境內則約一劑0.20美金左右<ref name=AHFS2014/>。

==作用机制==
{| class="wikitable sortable" style = "float: right; margin-left:15px; text-align:center"
|-
! 受体!! K<sub>i</sub> [nM]{{efn|These K<sub>i</sub> values are averaged binding affinities towards cloned human receptors when available.}} <br>(阿米替林)<ref name=PDSP>{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author = Roth, BL; Driscol, J | url = http://pdsp.med.unc.edu/pdsp.php | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 1 December 2013 | date = 12 January 2011 | deadurl = yes | archiveurl = https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php | archivedate =2013-11-08}}</ref><ref name = GG>{{cite book | author = Brunton, L; Chabner, B; Knollman, B | title = Goodman and Gilman's The Pharmacological Basis of Therapeutics | year = 2010 | publisher = McGraw-Hill Professional | isbn = 978-0-07-162442-8 | edition = 12th | location = New York }}</ref>!! K<sub>i</sub> [nM]{{efn|As with amitriptyline, these K<sub>i</sub>values are averaged binding affinities towards cloned human receptors when available.}} <br>([[去甲替林|去甲替林]])<ref name = PDSP/><ref name = GG/>
|-
| [[Serotonin_transporter|SERT]] || 3.13 || 16.5
|-
| [[Norepinephrine_transporter|NET]] || 22.4 || 4.37
|-
| [[Dopamine_transporter|DAT]] || 5380 || 3100
|-
| {{tsl|en|5-HT1A receptor||5-HT<sub>1A</sub>}} || 450 || 294
|-
| {{tsl|en|5-HT1B receptor||5-HT<sub>1B</sub>}} || 840 || - 
|-
| {{tsl|en|5-HT2A receptor||5-HT<sub>2A</sub>}} || 4.3 || 5
|-
| {{tsl|en|5-HT2C receptor||5-HT<sub>2C</sub>}} || 6.15 || 8.5
|-
| {{tsl|en|5-HT6 receptor||5-HT<sub>6</sub>}} || 103 || 148
|-
| {{tsl|en|5-HT7 receptor||5-HT<sub>7</sub>}} || 114 || -
|-
| {{tsl|en|Histamine H1 receptor||H<sub>1</sub>}} || 1.1 || 15.1
|-
| {{tsl|en|Histamine H3 receptor||H<sub>3</sub>}} || 1000 || -
|-
| {{tsl|en|Histamine H4 receptor||H<sub>4</sub>}} || 33.6 || -
|-
| {{tsl|en|Muscarinic acetylcholine receptor M1||M<sub>1</sub>}} || 12.9 || 40
|-
| {{tsl|en|Muscarinic acetylcholine receptor M2||M<sub>2</sub>}} || 11.8 || 110
|-
| {{tsl|en|Muscarinic acetylcholine receptor M3||M<sub>3</sub>}} || 25.9 || 50
|-
| {{tsl|en|Muscarinic acetylcholine receptor M4||M<sub>4</sub>}} || 7.2 || 84
|-
| {{tsl|en|Muscarinic acetylcholine receptor M5||M<sub>5</sub>}} || 19.9 || 97
|-
| {{tsl|en|alpha-1 adrenergic receptor||α<sub>1</sub>}} || 24 || 55
|-
| {{tsl|en|alpha-2 adrenergic receptor||α<sub>2</sub>}} || 690 || 2030
|-
| {{tsl|en|Dopamine D1 receptor||D<sub>1</sub>}} || 89 || -
|-
| [[Dopamine_D2_receptor|D<sub>2</sub>]] || 1460 || 2570
|-
| {{tsl|en|Dopamine D3 receptor||D<sub>3</sub>}} || 206 || -
|-
| {{tsl|en|Dopamine D5 receptor||D<sub>5</sub>}} || 170 || -
|-
| {{tsl|en|Sigma receptor||σ}} || 300 || 2000
|}
{{clear}}

==備註==
{{notelist|iger=}}

==引用==
{{reflist|2}}

{{抗抑郁药}}
{{Sigmaergics}}
{{Orexigenics}}
{{Hypnotics and sedatives}}
{{ADHD_pharmacotherapies}}
[[Category:抗抑郁药物|Category:抗抑郁药物]]
[[Category:三环类抗抑郁药|Category:三环类抗抑郁药]]
[[Category:叔胺|Category:叔胺]]
[[Category:多巴胺拮抗药|Category:多巴胺拮抗药]]
[[Category:H1受体拮抗剂|Category:H1受体拮抗剂]]
[[Category:蕈毒碱性受体拮抗剂|Category:蕈毒碱性受体拮抗剂]]
[[Category:血清素拮抗剂|Category:血清素拮抗剂]]
[[Category:血清素-去甲肾上腺素重摄取抑制剂|Category:血清素-去甲肾上腺素重摄取抑制剂]]
[[Category:Σ激动剂|Category:Σ激动剂]]